Tags Posts tagged with "$STEV"

$STEV

0 1157

Stevia Corp. Reports on Initial Sales Trends for Realhemp(TM) Branded Product Lines

INDIANAPOLIS, IN–(Marketwired – Sep 10, 2015) – Stevia Corp. (OTC PINK: STEV) (“Stevia Corp” or the “Company”), an international farm management company and healthcare company focused on the commercial development of products that support a healthy lifestyle, including stevia and hemp and their compounds, is pleased to provide an update on the initial success of its wholly-owned subsidiary Real Hemp LLC’s Realhemp™ product lines.

On August 3, 2015, Stevia Corp announced the unveiling of the Realhemp™ online store with 11 SKUs. During the first six weeks Real Hemp received orders from retail customers covering 20 states. An analysis of sales data revealed that a majority of customer orders included multiple products with the most popular product being hulled hemp seeds. Based on customer feedback and analysis of sales trends including product mix and size of each order, Real Hemp is moving forward with plans to launch additional hemp food based products over the next several months and will continue to promote and support the pursuit of a healthy lifestyle.

Stevia Corp. is also pleased to report that the Company and Real Hemp have nearly 16,000 followers spanning all of their social media channels to support a multidimensional sales strategy. Management is dedicated to continuing this successful campaign and retains two consultants to support a broad social media campaign and to analyze traffic and purchase data to optimize brand visibility and enhance sales in both current and future markets. Ultimately, the Company intends to leverage the US brand visibility being created to expand into other markets beyond North America.

The Real Hemp corporate website (www.realhemp.com) also received recognition as one of the 21st Annual Communicator Award of Excellence Winners — the highest honor award granted. The Communicator Awards is sanctioned and judged by the Academy of Interactive & Visual Arts (“AIVA”), an invitation-only group consisting of top-tier professionals from acclaimed media, communications, advertising, creative and marketing firms. AIVA members include executives from organizations such as Airtype Studio, Big Spaceship, Conde Nast, Coach, Disney, The Ellen DeGeneres Show, Estee Lauder, Fry Hammond Barr, Lockheed Martin, MTV Networks, Pitney Bowes, rabble+rouser, Sotheby’s Institute of Art, Time, Inc., Victoria’s Secret, Wired, and Yahoo!

George Blankenbaker, President of Stevia Corp. commented, “The Communicator Awards receives over 6,000 entries from companies and agencies of all sizes, making it one of the largest awards of its kind in the world and is the leading international awards program recognizing big ideas in marketing and communications. This award is a reflection of the quality team we have assembled, and specifically, the dedication of James DeRosa, who is largely responsible for the online efforts. We intend to continue focusing on expanding high quality online and social media platforms to support our long-term marketing and branding strategy. ”

Mr. Blankenbaker concluded, “We are excited about the initial launch of the Realhemp™ branded product lines, but we are even more excited about the work ahead of us, as we are fully committed to meeting the lifestyle needs of our customers while continuing to build long-term shareholder value in the process.”

About Stevia Corp. (OTC PINK: STEV)
Stevia Corp. is a farm management company and healthcare company focused on developing highly nutritional, high value products through proprietary plant breeding, excellent agricultural methodologies and innovative post-harvest techniques. Stevia Corp invests in R&D and IP acquisition and manages its own propagation, nursery and plantations as well as provides services to contract growers and other industry growers. Stevia Corp was founded on the principal of implementing socially responsible, sustainable, quality agribusiness solutions to maximize the long-term efficient production of nutritional crops. For additional information please visit: www.steviacorp.us.

About Real Hemp LLC
Real Hemp LLC is a wholly owned subsidiary of Stevia Corp. focused on commercializing the industrial hemp variety of cannabis sativa including its seeds, fiber and cannabinoids.

About the Hemp Industry Sector
Industrial Hemp is a crop that can be grown for food and non-food purposes. As a result of its numerous nutritional benefits, many new food products containing hemp seed and its oil are finding their way into the marketplace, including pasta, tortilla chips, salad dressings, snack products and frozen desserts. Hemp seed contains a complete protein and the seed oil is the richest source of essential fatty acids (Omega-6 and Omega-3) with the perfect ratio of 3:1. Hemp seed oil is also used in nutraceuticals and health care products.

As a fiber source, hemp is undergoing rapid growth as a natural fiber in everything from clothing and textiles to automotive composites. The fiber is also gaining popularity as insulation and other building materials.

The Hemp Industries Association (HIA) estimated that the 2014 retail sales value of hemp food and body care products in the United States was $200 million. When clothing, paper, auto parts, building materials and various other products are included, the HIA estimates that the total retail value of hemp products sold in the U.S. in 2014 to be at least $620 million. Total hemp retail sales in the U.S. have continued to grow steadily and the annual percent growth is estimated by the HIA to have progressed from 7.3% (2011), to 16.5% (2012), to 24% (2013), to 21.2% in 2014.

Industrial Hemp is distinct from marijuana and is defined as the plant Cannabis sativa L. and any part of such plant, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis.

Although it is legal to import and sell industrial hemp products in the U.S., it is not yet legal to commercially grow industrial hemp in the U.S. The 2013 farm bill was signed into law in February 2014 and contained a hemp amendment, Sec. 7606 Legitimacy of Industrial Hemp Research, which allows states that have already legalized the crop to cultivate hemp within the parameters of state agriculture departments and research institutions.

In January of 2015, The Industrial Hemp Farming Act was introduced in the House and Senate, H.R. 525 and S. 134 respectively. If passed, the bill would remove all federal restrictions on the cultivation of industrial hemp, and remove its classification as a Schedule 1 controlled substance.

About Cannabinoids
There are at least 85 different cannabinoids that have been identified in the cannabis plant. The most notable cannabinoid is tetrahydrocannabinol (THC), which is the primary psychoactive compound in marijuana (a variety of cannabis containing high levels of THC). Cannabidiol (CBD) is another major constituent of the plant and is a primary compound in Industrial Hemp (a variety of cannabis containing less than 0.3% THC on a dry weight basis).

Cannabinoids are a class of diverse chemical compounds that act on cannabinoid receptors. At present there are two known types of cannabinoid receptors, termed CB1 and CB2, with mounting evidence of more. The human brain has more cannabinoid receptors than any other G protein-coupled receptor type. CB1 receptors are found primarily in the brain and CB2 receptors are predominantly found in the immune system or immune-derived cells. Ligands for these receptor proteins include the endocannabinoids (produced naturally in the body by humans and animals), the phytocannabinoids (found in cannabis and some other plants), and synthetic cannabinoids (manufactured artificially).

In October 2003, U.S. patent U.S. Patent 6,630,507 entitled “Cannabinoids as antioxidants and neuroprotectants” was assigned to “The United States Of America As Represented By The Department Of Health And Human Services.” The patent was filed in April 1999 and listed as the inventors: Aidan J. Hampson, Julius Axelrod, and Maurizio Grimaldi, who all held positions at the National Institute of Mental Health (NIMH) in Bethesda, MD, which is part of the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). The patent mentions cannabidiol’s ability as an antiepileptic, to lower intraocular pressure in the treatment of glaucoma, lack of toxicity or serious side effects in large acute doses, its neuroprotectant properties, its ability to prevent neurotoxicity mediated by NMDA, AMPA, or kainate receptors; its ability to attenuate glutamate toxicity, its ability to protect against cellular damage, its ability to protect brains from ischemic damage, its anxiolytic effect, and its superior antioxidant activity which can be used in the prophylaxis and treatment of oxidation associated diseases.

Oxidative associated diseases include, without limitation, free radical associated diseases, such as ischemia, ischemic reperfusion injury, inflammatory diseases, systemic lupus erythematosus, myocardial ischemia or infarction, cerebrovascular accidents (such as a thromboembolic or hemorrhagic stroke) that can lead to ischemia or an infarct in the brain, operative ischemia, traumatic hemorrhage (for example a hypovolemic stroke that can lead to CNS hypoxia or anoxia), spinal cord trauma, Down’s syndrome, Crohn’s disease, autoimmune diseases (e.g. rheumatoid arthritis or diabetes), cataract formation, uveitis, emphysema, gastric ulcers, oxygen toxicity, neoplasia, undesired cellular apoptosis, radiation sickness, and others. Cannabinoids are believed to be particularly beneficial in the treatment of oxidative associated diseases of the CNS, because of the ability of the cannabinoids to cross the blood brain barrier and exert their antioxidant effects in the brain. It is believed that pharmaceutical composition of cannabinoids can be used for preventing, arresting, or treating neurological damage in Parkinson’s disease, Alzheimer’s disease and HIV dementia; autoimmune neurodegeneration of the type that can occur in encephalitis, and hypoxic or anoxic neuronal damage that can result from apnea, respiratory arrest or cardiac arrest, and anoxia caused by drowning, brain surgery or trauma (such as concussion or spinal cord shock).

Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, launching additional hemp food based products, sales strategy, the potential benefits of the cannabis plant, the commercialization of the cannabis plant, annual retail value of hemp products sold in the U.S., growth of industrial hemp product industry, potential uses of cannabinoids for treatment of various illnesses and diseases, product development and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2885545
Contact:

Stevia Corp. Investor Relations
Email: ir@steviacorp.com
Tel: +1-888-250-2566
Web: www.steviacorp.com

0 1225

Form 8-K for STEVIA CORP


11-Feb-2015

Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matter

ITEM 5.03 AMENDMENTS TO ARTICLES OF INCORPORATION OR BYLAWS; CHANGE IN FISCAL YEAR.On February 11, 2015, Stevia Corp., a Nevada corporation (the “Company”) received confirmation of the acceptance by the Nevada Secretary of State of the Company’s Certificate of Amendment to its Articles of Incorporation (the “Amendment”). The Amendment includes the authorization of 750,000,000 shares of common stock, par value $0.001 per share. As set forth in Item 5.07 below, the Company’s shareholders approved the Amendment at a special meeting of shareholders held on February 9, 2015. A copy of the Amendment is filed herewith as Exhibit 3.1 and incorporated herein by reference.

 

ITEM 5.07 SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.On February 9, 2015, the Company held a special meeting of shareholders (the “Special Meeting”) to approve the Amendment described in Item 5.03 above (the “Proposal”). The Company’s Board of Directors previously approved the Proposal subject to shareholder approval.

The presence, in person or by proxy, of the holders of a majority of the total number of shares entitled to vote constituted a quorum for the transaction of business at the Special Meeting. As of the record date, January 2, 2015, there were 198,239,385 shares of the Company’s common stock outstanding. At the Special Meeting, there were 152,113,804 shares, or approximately 76.73%, of common stock represented in person or by proxy.

Set forth below are the final voting results for the Proposal submitted to a vote of the shareholders at the Special Meeting. For more information on the Proposal, see the Company’s definitive proxy statement on Schedule 14A, as filed with the Securities and Exchange Commission on January 21, 2015 and supplemented January 30, 2015.

Proposal 1: To approve a proposed amendment to our Articles of Incorporation to increase the authorized number of shares of common stock available for issuance from 250,000,000 to 750,000,000 shares of common stock, par value $0.001 per share.

1 1517
marijuana stocks

Stevia Corp. Files Two Additional Provisional Patent Applications With the United States Patent and Trademark Office for a Cannabidiol (CBD) and Aspirin Formulation and a Cannabidiol and Naproxen Formulation to Treat Pain and Cardiovascular Disease

INDIANAPOLIS, IN–(Marketwired – Jan 29, 2015) -Stevia Corp. (OTCQB: STEV) (“Stevia Corp” or the “Company”), an international farm management company and healthcare company focused on the commercial development of products that support a healthy lifestyle, including stevia and hemp and their compounds, is pleased to announce the filing of two additional provisional patent applications with the United States Patent and Trademark Office (USPTO) for the treatment of pain and cardiovascular disease. The two separate applications include a provisional patent application that contains a formulation of naproxen and cannabidiol (CBD) and another application that contains a formulation of aspirin and cannabidiol. Stevia Corp. has now filed four provisional patent applications with the USPTO for four of the largest selling generic pain killing medications worldwide in combination with CBD.

“We believe that there will be significant advantages of using these four very effective drugs in combination with cannabidiol as opposed to using these drugs alone. Acetaminophen, Ibuprofen, Naproxen and Aspirin generate billions of dollars in sales each year. Our four provisional patent applications include 63 claims in total and we look forward to filing the utility patents over the next 12 months. We strongly believe that our intellectual property strategy, if successfully implemented, will provide us a competitive advantage over other healthcare companies using cannabinoids for human healthcare,” commented George Blankenbaker, President of Stevia Corp.

Mr. Blankenbaker concluded, “We have included other cannabinoids within our 63 patent claims including THC which we believe may also create significant value going forward.”

All four provisional patent applications were filed with the assistance of an intellectual property attorney with extensive experience in the healthcare industry. A provisional patent application is a legal document which establishes an early priority date for the benefit of claiming “first to file” status against other companies or individuals that may want to file a patent with similar claims after the filing date of our provisional patent.

Naproxen is a non-steroidal anti-inflammatory drug used to treat both pain and inflammation. Although the mechanism of action of NSAIDs such as naproxen are not completely understood, they are believed to work by inhibiting the synthesis of prostaglandins which are fat-like molecules that are involved in mediating inflammation, pain and fever. It achieves this synthesis by inhibiting cyclooxygenase, an enzyme that is present in various tissues of the body.

Aspirin is a painkiller and an anti-inflammatory agent with a long history of safe use. Aspirin is also frequently prescribed to individuals that have experienced an adverse cardiac event such as myocardial infarction. Furthermore, aspirin is used for the prevention of cardiac disease. Aspirin works for pain care and inflammation by inhibiting the synthesis of prostaglandins, which are fat-like molecules that are involved in mediating inflammation, pain and fever. Aspirin also has an antiplatelet effect by inhibiting the production of thromboxane. Under normal circumstances, thromboxane binds platelet molecules together to create a patch over a damaged section of a blood vessel. If and when the platelet patch becomes too large, it can restrict blood flow resulting in a heart attack or stroke. If atherosclerosis is present or an individual’s family has a history of heart disease, a daily dose of aspirin may be prescribed after a heart attack or to prevent another heart attack. In many cases, a daily dose of aspirin is prescribed for the prevention and management of signs of cardiovascular disease.

Cannabidiol (CBD) is a cannabinoid that is present in most varieties of the cannabis sativa and cannabis indica plants. Cannabinoids are unique to the cannabis sativa and cannabis indica plants. Unlike some of the other molecules found in varieties of the cannabis plant, it is non-psychoactive and it is not believed to have any addictive properties. It is also extremely well tolerated at high doses with little or no adverse side effects. Cannabidiol catapulted into a national story after being an important part of the 2013 CNN documentary “Weed.”

A provisional patent application is not required to have a formal patent claim or an oath or declaration. However, an applicant who files a provisional patent must file a non-provisional patent with the USPTO within 12 months of the filing of the provisional patent application in order to benefit from the priority date. Most importantly, the provisional application allows the owner of the patent to market products that are believed to be covered by the patent application with “patent pending” status. Stevia Corp filed its four applications pursuant to other country’s patent statutes, which will allow Stevia Corp to claim the priority date in many other countries besides the United States upon the filing of a non-provisional patent application. There is no guarantee that filing a provisional or a non-provisional patent application will result in a successful registration with the USPTO.

About Stevia Corp. (OTCQB: STEV)
Stevia Corp. is a farm management company and healthcare company focused on developing highly nutritional, high value products through proprietary plant breeding, excellent agricultural methodologies and innovative post-harvest techniques. Stevia Corp invests in R&D and IP acquisition and manages its own propagation, nursery and plantations as well as provides services to contract growers and other industry growers. Stevia Corp was founded on the principal of implementing socially responsible, sustainable, quality agribusiness solutions to maximize the long-term efficient production of nutritional crops. For additional information please visit: www.steviacorp.us.

About the Hemp Industry Sector
Hemp is a crop that can be grown for food and non-food purposes. As a result of its numerous nutritional benefits, many new food products containing hemp seed and its oil are finding their way into the marketplace, including protein mixes, pasta, tortilla chips, salad dressings, snack products and frozen desserts. Non-dairy hemp “milk” beverages, which provide significant amounts of omega 3 essential fatty acids (EFAs) and protein, are also available. Hemp oil is also used in nutraceuticals and health care products as well as industrial applications.

As an industrial fiber source, hemp is undergoing rapid growth as a natural fiber in everything from clothing and textiles to automotive composites. The fiber is also gaining popularity as a building material such as insulation.

The Hemp Industries Association (HIA) estimated that the 2013 retail sales value of hemp food and body care products in the United States was $184 million. When clothing, paper, auto parts, building materials and various other products are included, the HIA estimates that the total retail value of hemp products sold in the US in 2013 to be at least $581 million and included more than 50,000 products.

Notice Regarding Forward-Looking Statements

This news release contains “forward-looking statements” as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, filing patent applications, product development, development of a product containing both naproxen and cannabidiol, development of a product containing both aspirin and cannabidiol, potential of CBD for treating diseases, annual retail value of hemp products sold in the U.S., growth of industrial hemp product industry, product development and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

0 1366
marijuana stocks

Stevia Corp. Provides Spring Harvest Guidance

INDIANAPOLIS, IN–(Marketwired – Jan 28, 2015) -Stevia Corp. (OTCQB: STEV) (“Stevia Corp” or the “Company”), an international farm management company and healthcare company focused on the commercial development of products that support a healthy lifestyle, including stevia and hemp and their compounds, is pleased to announce that the company expects the current 2015 spring harvest to exceed 3,000 tons achieving a 50% increase over the 2014 spring harvest and a 300% increase over the 2013 spring harvest.

The majority of the spring harvest will occur during the Company’s fourth quarter ending March 31, 2015 with the balance occurring during the first quarter ending June 30, 2015. The Company also harvested additional test fields during the quarter ending December 31, 2014.

George Blankenbaker, Stevia Corp President, commented, “Now that we have established a significant production base of a diversified crop portfolio, much of the focus during 2015 will be to develop higher margin and value added products. Industrial Hemp and its related products will constitute a significant portion of this effort as we explore several commercial opportunities.”

Mr. Blankenbaker continued, “We will continue developing our core business of farm management and post harvest processing which includes continuing discussions with our major Korean customer to establish a joint manufacturing facility in Vietnam and expanding our aqua culture production to South America to produce seafood for major US restaurant groups and European buyers. However, we believe the greatest potential value will be generated by our focus on intellectual property surrounding the commercialization of cannabidiol and industrial hemp and we intend to file several more provisional patents in this space.”

About Stevia Corp. (OTCQB: STEV)
Stevia Corp. is a farm management company and healthcare company focused on developing highly nutritional, high value products through proprietary plant breeding, excellent agricultural methodologies and innovative post-harvest techniques. Stevia Corp invests in R&D and IP acquisition and manages its own propagation, nursery and plantations as well as provides services to contract growers and other industry growers. Stevia Corp was founded on the principal of implementing socially responsible, sustainable, quality agribusiness solutions to maximize the long-term efficient production of nutritional crops. For additional information please visit: www.steviacorp.us.

About the Hemp Industry Sector
Hemp is a crop that can be grown for food and non-food purposes. As a result of its numerous nutritional benefits, many new food products containing hemp seed and its oil are finding their way into the marketplace, including protein mixes, pasta, tortilla chips, salad dressings, snack products and frozen desserts. Non-dairy hemp “milk” beverages, which provide significant amounts of omega 3 essential fatty acids (EFAs) and protein, are also available. Hemp oil is also used in nutraceuticals and health care products as well as industrial applications.

As an industrial fiber source, hemp is undergoing rapid growth as a natural fiber in everything from clothing and textiles to automotive composites. The fiber is also gaining popularity as a building material such as insulation.

The Hemp Industries Association (HIA) estimated that the 2013 retail sales value of hemp food and body care products in the United States was $184 million. When clothing, paper, auto parts, building materials and various other products are included, the HIA estimates that the total retail value of hemp products sold in the US in 2013 to be at least $581 million and included more than 50,000 products.

Notice Regarding Forward-Looking Statements

This news release contains “forward-looking statements” as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the size and timing of the spring harvest, development of higher margin products in 2015, exploration of commercial opportunities in the industrial hemp market, potential joint manufacturing facility in Vietnam, expanding aqua culture production in South America, intellectual property development, patent filings, annual retail value of hemp products sold in the U.S., growth of industrial hemp product industry, product development and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

0 1349

Form 8-K for STEVIA CORP

27-Jan-2015

Other Events, Financial Statements and Exhibits

ITEM 8.01. OTHER EVENTS.On January 26, 2015, Stevia Corp., a Nevada corporation (the “Company”) issued a press release announcing an investor update conference call to be held on January 29, 2015 at 4:30 PM EST. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

 

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

Exhibit No.                   Exhibit Description
-----------                   -------------------

  99.1        Press Release of the Company, dated January 26, 2015

The information set forth in Exhibit 99.1 attached hereto is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, and shall not be deemed incorporated by reference in any filing with the Securities and Exchange Commission under the Securities Exchange Act of 1934 or the Securities Act of 1933, whether made before or after the date hereof and irrespective of any general incorporation by reference language in any filing.

Portions of this report may constitute “forward-looking statements” defined by federal law. Although the Company believes any such statements are based on reasonable assumptions, there is no assurance that the actual outcomes will not be materially different. Any such statements are made in reliance on the “safe harbor” protections provided under the Private Securities Litigation Reform Act of 1995. Additional information about issues that could lead to material changes in the Company’s performance is contained in the Company’s filings with the Securities and Exchange Commission and may be accessed at www.sec.gov.

0 1279

Stevia Corp. Announces Investor Update Conference Call

INDIANAPOLIS, IN–(Marketwired – Jan 26, 2015) -Stevia Corp. (OTCQB: STEV) (“Stevia Corp” or the “Company”), an international farm management company and healthcare company focused on the commercial development of products that support a healthy lifestyle, including stevia and hemp and their compounds, is pleased to announce that the company will host a conference call on January 29, 2015 at 4:30 PM EST to discuss recent corporate news and its business goals for 2015. All shareholders as well as interested parties are invited and encouraged to participate.

The call can be accessed live by dialing (877) 440-5803. International callers can access the call by dialing (719) 325-4767. A simultaneous webcast of the call will be available by visitinghttp://www.steviacorp.com and clicking on the Webcast link.

The entire call will be archived including questions and answers and will we be available on the company’s website after the call. The company will also provide a written transcript of the corporate presentation as part of a Schedule 14A filing with the United States Securities and Exchange Commission to be filed shortly after the call ends.

The company expects a significant number of participants on the call. Therefore, investors are encouraged to send questions immediately by emailing questions to questions@steviacorp.com. This will also be the format to ask questions during the call but to ensure that the company has time to review and respond to questions, the company is encouraging shareholders to email their questions as soon as possible prior to the call.

About Stevia Corp. (OTCQB: STEV)
Stevia Corp. is a farm management company and healthcare company focused on developing highly nutritional, high value products through proprietary plant breeding, excellent agricultural methodologies and innovative post-harvest techniques. Stevia Corp invests in R&D and IP acquisition and manages its own propagation, nursery and plantations as well as provides services to contract growers and other industry growers. Stevia Corp was founded on the principal of implementing socially responsible, sustainable, quality agribusiness solutions to maximize the long-term efficient production of nutritional crops. For additional information please visit: www.steviacorp.us.

About the Hemp Industry Sector
Hemp is a crop that can be grown for food and non-food purposes. As a result of its numerous nutritional benefits, many new food products containing hemp seed and its oil are finding their way into the marketplace, including protein mixes, pasta, tortilla chips, salad dressings, snack products and frozen desserts. Non-dairy hemp “milk” beverages, which provide significant amounts of omega 3 essential fatty acids (EFAs) and protein, are also available. Hemp oil is also used in nutraceuticals and health care products as well as industrial applications.

As an industrial fiber source, hemp is undergoing rapid growth as a natural fiber in everything from clothing and textiles to automotive composites. The fiber is also gaining popularity as a building material such as insulation.

The Hemp Industries Association (HIA) estimated that the 2013 retail sales value of hemp food and body care products in the United States was $184 million. When clothing, paper, auto parts, building materials and various other products are included, the HIA estimates that the total retail value of hemp products sold in the US in 2013 to be at least $581 million and included more than 50,000 products.

Notice Regarding Forward-Looking Statements

This news release contains “forward-looking statements” as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, annual retail value of hemp products sold in the U.S., growth of industrial hemp product industry, product development and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

Contact:

Stevia Corp. Investor Relations
Email: ir@steviacorp.com

0 1089

Stevia Corp. Announces Investor Update Conference Call

INDIANAPOLIS, IN–(Marketwired – Jan 26, 2015) -Stevia Corp. (OTCQB: STEV) (“Stevia Corp” or the “Company”), an international farm management company and healthcare company focused on the commercial development of products that support a healthy lifestyle, including stevia and hemp and their compounds, is pleased to announce that the company will host a conference call on January 29, 2015 at 4:30 PM EST to discuss recent corporate news and its business goals for 2015. All shareholders as well as interested parties are invited and encouraged to participate.

The call can be accessed live by dialing (877) 440-5803. International callers can access the call by dialing (719) 325-4767. A simultaneous webcast of the call will be available by visitinghttp://www.steviacorp.com and clicking on the Webcast link.

The entire call will be archived including questions and answers and will we be available on the company’s website after the call. The company will also provide a written transcript of the corporate presentation as part of a Schedule 14A filing with the United States Securities and Exchange Commission to be filed shortly after the call ends.

The company expects a significant number of participants on the call. Therefore, investors are encouraged to send questions immediately by emailing questions to questions@steviacorp.com. This will also be the format to ask questions during the call but to ensure that the company has time to review and respond to questions, the company is encouraging shareholders to email their questions as soon as possible prior to the call.

About Stevia Corp. (OTCQB: STEV)
Stevia Corp. is a farm management company and healthcare company focused on developing highly nutritional, high value products through proprietary plant breeding, excellent agricultural methodologies and innovative post-harvest techniques. Stevia Corp invests in R&D and IP acquisition and manages its own propagation, nursery and plantations as well as provides services to contract growers and other industry growers. Stevia Corp was founded on the principal of implementing socially responsible, sustainable, quality agribusiness solutions to maximize the long-term efficient production of nutritional crops. For additional information please visit: www.steviacorp.us.

About the Hemp Industry Sector
Hemp is a crop that can be grown for food and non-food purposes. As a result of its numerous nutritional benefits, many new food products containing hemp seed and its oil are finding their way into the marketplace, including protein mixes, pasta, tortilla chips, salad dressings, snack products and frozen desserts. Non-dairy hemp “milk” beverages, which provide significant amounts of omega 3 essential fatty acids (EFAs) and protein, are also available. Hemp oil is also used in nutraceuticals and health care products as well as industrial applications.

As an industrial fiber source, hemp is undergoing rapid growth as a natural fiber in everything from clothing and textiles to automotive composites. The fiber is also gaining popularity as a building material such as insulation.

The Hemp Industries Association (HIA) estimated that the 2013 retail sales value of hemp food and body care products in the United States was $184 million. When clothing, paper, auto parts, building materials and various other products are included, the HIA estimates that the total retail value of hemp products sold in the US in 2013 to be at least $581 million and included more than 50,000 products.

Notice Regarding Forward-Looking Statements

This news release contains “forward-looking statements” as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, annual retail value of hemp products sold in the U.S., growth of industrial hemp product industry, product development and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

Contact:

Stevia Corp. Investor Relations
Email: ir@steviacorp.com
Tel: +1-888-250-2566
Web: www.steviacorp.com

1 1737

Stevia Corp. Files Second Key Provisional Patent Application with the United States Patent and Trademark Office for a Cannabidiol (CBD) and Ibuprofen Formulation to Treat Pain

Company to Pursue Broad Intellectual Property Strategy Related to Specific Cannabinoids to Establish Competitive Position through its Real Hemp Wholly-Owned Subsidiary

INDIANAPOLIS, Jan. 20, 2015 /PRNewswire/ –Stevia Corp. (STEV) (“Stevia Corp” or the “Company”), an international farm management company and healthcare company focused on the commercial development of products that support a healthy lifestyle, including stevia and hemp and their compounds, is pleased to announce the filing of a second important provisional patent application with the United States Patent and Trademark Office for the treatment of pain using ibuprofen and Cannabidiol (CBD).

The provisional patent application closely follows the company’s previously announced first provisional patent application for pain comprising acetaminophen and CBD. As in the previously filed application, this patent includes multiple claims including but not limited to combinations of cannabinoids including CBD and ibuprofen for the treatment of pain. The provisional patent application was filed with the assistance of an intellectual property attorney with extensive experience in the healthcare industry. A provisional patent application is a legal document which establishes an early priority date for the benefit of claiming “first to file” status against other companies or individuals that may want to file a patent with similar claims after the filing date of our provisional patent.

Ibuprofen is a non-steroidal drug that can be used to relieve pain and reduce fever. Ibuprofen is also widely recognized as a non-steroidal anti-inflammatory drug (NSAID). Like many NSAIDs, ibuprofen works by inhibiting the synthesis of prostaglandins which are fat-like molecules that are involved in mediating inflammation, pain and fever. It achieves this synthesis by inhibiting cyclooxygenase, an enzyme that is present in various tissues of the body. Ibuprofen is the active ingredient in popular OTC (over-the-counter) analgesics such as Advil® and Motrin®. For most pain sufferers, use of these drugs requires a long term, daily dosing regimen.

Cannabidiol (CBD) is a cannabinoid that is present in most varieties of the cannabis sativa and cannabis indica plants. Cannabinoids are unique to the cannabis sativa and cannabis indica plants. Unlike some of the other molecules found in varieties of the cannabis plant, it is non-psychoactive and it is not believed to have any addictive properties. It is also extremely well tolerated at high doses with little or no side effects. Cannabidiol catapulted into a national story after being an important part of the 2013 CNN documentary “Weed”.

George Blankenbaker, Stevia Corp commented, “This is our second key provisional patent application related to pain which is one of the largest healthcare markets in the world. In the past two weeks, we have announced our intention to secure patents and to launch products that contain specific cannabinoids in combination with either ibuprofen or acetaminophen. Ibuprofen and acetaminophen are two of the largest selling OTC drugs in the world and are the key ingredients behind Motrin® and Tylenol®.”

Mr. Blankenbaker continued, “As the market for both prescription and non-prescription pain reliever products continues to grow, unfortunately the amount of people experiencing side effects and the amount of people addicted to prescription pain killers also continues to grow. Our goal is to develop a painkiller that first and foremost works. Second, it must minimize adverse side effects. Finally, it must reduce the chance of addiction. We believe we will be able to develop these three attributes in a pain killer and as we stated in the previous announcement, we are exploring the possibility of partnering with a large pharmaceutical company that has extensive experience in the pain care market and particularly, experience with products that contain these two OTC medicines.”

A provisional patent application is not required to have a formal patent claim or an oath or declaration. However, an applicant who files a provisional patent must file a non-provisional patent with the United States Patent and Trademark Office within 12 months of the filing of the provisional patent application in order to benefit from the priority date. Most importantly, the provisional application allows the owner of the patent to market products that are believed to be covered by the patent application with “patent pending” status. Stevia Corp filed its application pursuant to other country’s patent statutes, which will allow Stevia Corp to claim the priority date in many other countries besides the United States upon the filing of a non-provisional patent application.

Tylenol is a registered trademark of Johnson and Johnson. Motrin is a registered trademark of McNeil Consumer Healthcare. Advil is a registered trademark of Pfizer.

About Stevia Corp. (OTCQB: STEV)

Stevia Corp. is a farm management company and healthcare company focused on developing highly nutritional, high value products through proprietary plant breeding, excellent agricultural methodologies and innovative post-harvest techniques.  Stevia Corp invests in R&D and IP acquisition and manages its own propagation, nursery and plantations as well as provides services to contract growers and other industry growers.  Stevia Corp was founded on the principal of implementing socially responsible, sustainable, quality agribusiness solutions to maximize the long-term efficient production of nutritional crops. For additional information please visit: www.steviacorp.us.

About the Hemp Industry Sector

Hemp is a crop that can be grown for food and non-food purposes. As a result of its numerous nutritional benefits, many new food products containing hemp seed and its oil are finding their way into the marketplace, including protein mixes, pasta, tortilla chips, salad dressings, snack products and frozen desserts. Non-dairy hemp “milk” beverages, which provide significant amounts of omega 3 essential fatty acids (EFAs) and protein, are also available. Hemp oil is also used in nutraceuticals and health care products as well as industrial applications.

As an industrial fiber source, hemp is undergoing rapid growth as a natural fiber in everything from clothing and textiles to automotive composites. The fiber is also gaining popularity as a building material such as insulation.

The Hemp Industries Association (HIA) estimated that the 2013 retail sales value of hemp food and body care products in the United States was $184 million. When clothing, paper, auto parts, building materials and various other products are included, the HIA estimates that the total retail value of hemp products sold in the US in 2013 to be at least $581 million and included more than 50,000 products.

Notice Regarding Forward-Looking Statements

This news release contains “forward-looking statements” as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, filing patent applications, product development, development of a product containing both ibuprofen and cannabidiol, development of a product containing both acetaminophen and cannabidiol, potential joint venture for future product development, potential of CBD for treating diseases, annual retail value of hemp products sold in the U.S., growth of industrial hemp product industry, product development and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

Contact:

Stevia Corp. Investor Relations
Email: ir@steviacorp.com
Tel:     +1-888-250-2566
Web:   www.steviacorp.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/stevia-corp-files-second-key-provisional-patent-application-with-the-united-states-patent-and-trademark-office-for-a-cannabidiol-cbd-and-ibuprofen-formulation-to-treat-pain-300022756.html

1 1493

Stevia Corp. Files Key Provisional Patent Application With the United States Patent and Trademark Office for Cannabidiol (CBD) and Acetaminophen Formulation to Treat Pain

INDIANAPOLIS, IN–(Marketwired – Jan 15, 2015) -Stevia Corp. (OTCQB: STEV)

  • Acetaminophen is one of the top selling generic drugs worldwide
  • Cannabidiol gained national attention during the past 24 months
  • Company’s application includes over 10 different claims

Stevia Corp. (OTCQB: STEV) (“Stevia Corp” or the “Company”), an international farm management company and healthcare company focused on the commercial development of products that support a healthy lifestyle, including stevia and hemp and their compounds, is pleased to announce the filing of an important provisional patent application with the United States Patent and Trademark Office for the treatment of pain using acetaminophen and Cannabidiol (CBD). A provisional patent application is a legal document which establishes an early priority date for the benefit of claiming “first to file” status against other companies or individuals that may want to file for a patent with similar claims after the filing date of our provisional application.

Acetaminophen is a pain reliever with a long history of effective use and when consumed as prescribed, it is a well-tolerated and safe medication. Acetaminophen belongs to a class of drugs known as non-opioid analgesics. It is found in many cold medications and in popular products such as Tylenol® (recognized as a registered trademark of Johnson and Johnson) and has been one of the largest selling OTC (over-the-counter) drugs in the world generating billions of revenue each year.

Cannabidiol (CBD) is a molecule which is present in most varieties of the cannabis sativa and cannabis indica plants. Unlike some of the other molecules found in varieties of the cannabis plant, it is non-psychoactive and it is not believed to have any addictive properties. It is also extremely well tolerated at high doses with little or no side effects. Cannabidiol catapulted into a national story after being an important part of the 2013 CNN documentary “Weed” (commonly referred to as the Charlotte’s Web Story). The documentary highlighted the story of a little girl, Charlotte Figi, who was suffering from Dravet syndrome, a condition that produces daily epileptic seizures in children. Many people now credit the Charlotte’s web story for creating the sweeping changes in medical marijuana laws throughout the United States.

George Blankenbaker, Stevia Corp. commented, “Over the past 12 months, we have been building an internal business plan which we believe will create significant value for our shareholders. It was important that we did not disclose details of these plans until we had the proper protection.”

Mr. Blankenbaker continued, “We understand that communication is critical to maintain shareholder support and will continue to update shareholders when important material events occur. The Company must carefully manage disclosure of future plans and do so in a time frame and manner that is informative to shareholders without damaging the Company’s competitive position. We believe the application that we have filed with the USPTO allows the Company to pursue a strategic and broad business strategy to legally market and sell a product that can be sold as an OTC healthcare product. Alternatively, we are exploring the possibility of partnering with a large pharmaceutical company that has extensive experience in either the pain care market or experience with acetaminophen.”

Mr. Blankenbaker concluded, “At the advice of our intellectual property attorney, we are not going to announce details about the claims within our provisional patent application. We will simply add that the claims are well thought out and we believe future planned developments will put us in an enviable position among all companies in the acetaminophen and cannabidiol markets. We welcome our shareholders and prospective investors to research the size of the acetaminophen market and to also research the worldwide interest being generated for cannabidiol.”

A provisional patent application is not required to have a formal patent claim or an oath or declaration. However, an applicant who files a provisional application must file a non-provisional application with the United States Patent and Trademark Office within 12 months of the filing of the provisional patent application in order to benefit from the priority date. Most importantly, the provisional application allows the owner to market products that are believed to be covered by the patent application with “patent pending” status. Stevia Corp filed its application pursuant to other country’s patent statutes, which will allow Stevia Corp to claim the priority date in many other countries besides the United States upon the filing of a non-provisional patent application.

The Company filed its patent application with the aid of an intellectual property law firm with extensive experience in pharmaceutical and biotechnology patents.

About Stevia Corp. (OTCQB: STEV)
Stevia Corp is a farm management company and healthcare company focused on developing highly nutritional, high value products through proprietary plant breeding, excellent agricultural methodologies and innovative post-harvest techniques. Stevia Corp invests in R&D and IP acquisition and manages its own propagation, nursery and plantations as well as provides services to contract growers and other industry growers. Stevia Corp was founded on the principal of implementing socially responsible, sustainable, quality agribusiness solutions to maximize the long-term efficient production of nutritional crops. For additional information please visit: www.steviacorp.us.

About the Hemp Industry Sector
Hemp is a crop that can be grown for food and non-food purposes. As a result of its numerous nutritional benefits, many new food products containing hemp seed and its oil are finding their way into the marketplace, including protein mixes, pasta, tortilla chips, salad dressings, snack products and frozen desserts. Non-dairy hemp “milk” beverages, which provide significant amounts of omega 3 essential fatty acids (EFAs) and protein, are also available. Hemp oil is also used in nutraceuticals and health care products as well as industrial applications.

As an industrial fiber source, hemp is undergoing rapid growth as a natural fiber in everything from clothing and textiles to automotive composites. The fiber is also gaining popularity as a building material such as insulation.

The Hemp Industries Association (HIA) estimated that the 2013 retail sales value of hemp food and body care products in the United States was $184 million. When clothing, paper, auto parts, building materials and various other products are included, the HIA estimates that the total retail value of hemp products sold in the US in 2013 to be at least $581 million and included more than 50,000 products.

Notice Regarding Forward-Looking Statements

This news release contains “forward-looking statements” as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, development of a product containing both acetaminophen and cannabidiol, potential joint venture for future product development, potential of CBD for treating diseases, annual retail value of hemp products sold in the U.S., growth of industrial hemp product industry, product development and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

Contact:

Stevia Corp. Investor Relations
Email: ir@steviacorp.com
Tel: +1-888-250-2566
Web: www.steviacorp.com

0 7196

Stevia Corp. Appoints Dr. Jerry Smartt to Board of Directors and Welcomes Veteran Research Scientist to Advisory Board

Company Beefs Up Its Medical and Research Expertise as It Focuses on Commercializing CBD

INDIANAPOLIS, IN–(Marketwired – Jan 12, 2015) -Stevia Corp. (OTCQB: STEV) (“Stevia Corp” or the “Company”), an international farm management company focused on the commercial development of products that support a healthy lifestyle, including stevia and hemp and their extracts, is pleased to announce the appointment of Dr. Jerry W Smartt Jr. to its Board of Directors and Prof. Xie Haihui as research advisor.

Dr. Smartt is a board-certified neurologist and established Smartt Neurology, PC, in 2004 and Smartt Services, LLC in 2005 to provide private practice neurology and contracted services. Dr. Smartt provides contracted wellness center services to the Atterbury Job Corps Center and serves the Indiana Family and Social Services Administration as the physician contractor performing medical chart review and evaluation of disability for the Indiana Disability Determination Bureau. Dr. Smartt also serves as Volunteer Clinical Assistant Professor of Neurology for Indiana University School of Medicine and Attending Staff Physician of Neurology for Indianapolis VA Medical Center.

Prof. Xie joins the Company with an extensive research background and is the first author or corresponding author of 19 science citation index papers, holds 3 patents and is currently a professor at South China Institute of Botany as well as a supervisor of postgraduates for master degrees and doctorate degrees and is a member of the Chinese Chemical Society and Japanese Pharmaceutical Society. His professional experience includes Research Assistant, Assistant Professor and Associate professor at the South China Institute of Botany, and visiting scholar and research assistant to Kyoto Pharmaceutical University.

George Blankenbaker, Stevia Corp President, commented, “Dr. Smartt and Prof. Xie will provide significant value as we and our subsidiaries focus on both the protocols to produce CBD and the commercial applications for our IP and products. Dr. Smartt and Prof. Xie also have extensive networks in the medical and research communities to attract additional talent to the company.”

The Company believes that its wholly-owned subsidiary, Stevia Technew Ltd.’s focus on CBD will create significant value for the company. CBD is one of at least 85 cannabinoids (chemical compounds found in both industrial hemp and marijuana) and hundreds of scientific studies have demonstrated CBD’s potential in addressing a wide range of serious conditions, including rheumatoid arthritis, diabetes, chronic pain, schizophrenia, PTSD, epilepsy, Alzheimer’s, Parkinson’s, HIV dementia and many others. CBD is also non-psychoactive and avoids toxicity that is encountered with psychoactive cannabinoids at high doses.

Further details of the Company’s business, finances, appointments and agreements can be found as part of the Company’s continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934, as amended, filed with the Securities and Exchange Commission’s (“SEC”) EDGAR database. For more information visit: www.steviacorp.us.

About Stevia Corp. (OTCQB: STEV)
Stevia Corp. is a farm management company focused on developing highly nutritional, high value products through proprietary plant breeding, excellent agricultural methodologies and innovative post-harvest techniques. Stevia Corp invests in R&D and IP acquisition and manages its own propagation, nursery and plantations as well as provides services to contract growers and other industry growers. Stevia Corp was founded on the principal of implementing socially responsible, sustainable, quality agribusiness solutions to maximize the long-term efficient production of nutritional crops. For additional information please visit: www.steviacorp.us.

About the Hemp Industry Sector
Hemp is a crop that can be grown for food and non-food purposes. As a result of its numerous nutritional benefits, many new food products containing hemp seed and its oil are finding their way into the marketplace, including pasta, tortilla chips, salad dressings, snack products and frozen desserts. Non-dairy hemp “milk” beverages, which provide significant amounts of omega 3 essential fatty acids (EFAs) and protein, are also available. Hemp oil is also used in nutraceuticals and health care products.

As a fiber source, hemp is undergoing rapid growth as a natural fiber in everything from clothing and textiles to automotive composites. The fiber is also gaining popularity as insulation.

The Hemp Industries Association (HIA) estimated that the 2013 retail sales value of hemp food and body care products in the United States was $184 million. When clothing, paper, auto parts, building materials and various other products are included, the HIA estimates that the total retail value of hemp products sold in the US in 2013 to be at least $581 million.

Seed and fiber uses for industrial hemp are growing rapidly and have increased over 300 percent, serving more than 50,000 products, in the past few years. Much of that growth is coming from the increased sales of hemp food products.

Notice Regarding Forward-Looking Statements

This news release contains “forward-looking statements” as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, potential of CBD for treating diseases, annual retail value of hemp products sold in the U.S., growth of industrial hemp product industry, product development and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

Contact:

Stevia Corp. Investor Relations
Email: ir@steviacorp.com
Tel: +1-888-250-2566
Web: www.steviacorp.com

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
Ad Placements